CTRI/2020/02/023247已完成未知
A single centre, site randomized, double-blind, comparative study to evaluate the impact of topical application of FOS and GOS on skin hydration, barrier function, and microbiome regulation in human adult subjects with dry, flaky skin, otherwise healthy.
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age 30 to 55 years (both inclusive) at the time of consent.
- •2.Sex: Male or non-pregnant/non-lactating females.
- •3.Females of Childbearing potential must have a negative urine pregnancy test performed on screening visit.
- •4.Subject who is having good general health as per medical history.
- •5.Subject with dry skin evaluated by Corneometer reading in between 30 to 40 a.u. unit on each forearm.
- •6.Subject with mild to moderate dry skin will be included as determined by dermatologist/dermatologist validated scorer using 4 point scale1.
- •7.Subject with willingness to avoid usage of soaps, cleansers or any other moisturizers/lotions/creams/oils other than the test product on the test site 7 days prior and throughout the entire study duration.
- •8.Subject must be able to understand and provide written informed consent to participate in the study.
- •9.Subject should be willing and able to follow the study directions to participate in the study.
排除标准
- •1.Subject with current use or use in the past 3 months of antimicrobial or steroidal drugs or any prescription medication or supplementâ??s.
- •2.Subject with medical history (past and present) of significant dermatologic diseases or conditions, such as atopy, psoriasis, eczema, atopic dermatitis, vitiligo or other conditions known to alter skin appearance or physiologic response (e.g. porphyria) chronic urticaria, or sunburn, rashes.
- •3.Subject with history of medical conditions affecting immune status (e.g., rheumatoid arthritis, heart failure, hepatitis C, HIV).
- •4.Subject with application of any topical products (cream /lotion/soap/Cleanser/coconut oil/mustard oils/ dairy products or any other cosmetic applications, mehndi, tattoo, scar and excessive terminal hair) for 7 days before the study and during the study.
- •5.Female volunteers who identified Pregnant during the study period or are lactating.
- •6.Subject with history of drug and alcohol abuse.
- •7.Subject participating in a similar clinical study, currently or during the previous 90 days.
- •8.Subject with any relevant surgical treatment during the previous two months or planned during the study.
- •9.Any subject, in the investigators opinion not considered suitable for enrollment.
研究者
相似试验
进行中(未招募)
不适用
A single centre, randomised, double-blind, double-dummy, placebo-and active-controlled, 3-way cross-over study to evaluate the 24 hour FEV1 profile of a single dose of CHF 5188 pMDI (400/4 mcg QD) (fixed combination budesonide/carmoterol 200/2 mcg) in adults patients with moderate or severe persistent asthmaModerate or Severe Persistent AsthmaMedDRA version: 9.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2008-001773-15-GBChiesi Farmaceutici SpA42
进行中(未招募)
不适用
A randomized, , double-blind, single centre, intra-individual comparison study with repeated application to assess the wound-healing efficacy of a 5 % Dexpanthenol ointment compared with placebo in patients with superficial, abrasive wounds.Epidermal abrasive woundsEUCTR2006-005508-14-DEBayer Consumer Care AG
已完成
不适用
A single-center, randomized, double-blind, double-dummy, placebo- and active-controlled, 4-way cross-over study to assess next-day driving performance following single and multiple evening administrations of ACT-541468 in middle-aged and elderly subjects.InsomniaNL-OMON48154Idorsia Pharaceuticals Ltd.56
已完成
1 期
A phase 1 clinical trial to evaluate the safety, pharmacokinetics/pharmacodynamics, and immunogenicity of single and multiple ascending subcutaneous doses of RS2102 in healthy adult subjectsInflammatory and Immune System - Autoimmune diseasesSystemic lupus erythematosusACTRN12621001161819Atridia Pty Ltd56
已完成
不适用
A single-center, randomized, double-blind, two-period cross-over study to investigate the effect of a single intravenous dose of rifampicin on the pharmacokinetics of ACT-246475 in healthy subjects.Acute myocardial infarctionNL-OMON46064Idorsia Pharmaceuticals Ltd14
